Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies
Shots:
- Biocytogen to receive an up front & will be eligible to receive an option-exercise fee, development & commercial milestones along with royalties upon exercise of each option
- ADC will obtain the license from Biocytogen to evaluate mAb/or biparatopic Abs against 3 tumor targets developed through Biocytogen’s Project Integrum (RenMice HiTS Platform) & also get the option to license selected Abs for development & commercialization globally along with responsibility for the feasibility studies if the option is exercised. Biocytogen reserves all global rights for these Abs
- The agreement will combine Biocytogen’s strength in Ab development with ADC’s expertise, and track record in payload and linker technology to develop novel ADC therapies
Ref: Businesswire| Image: Biocytogen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.